Schizophrenia; A Review on Promising Drug Delivery Systems

Author(s): Ece Ö. Bülbül, Ioannis D. Karantas, Mehmet E. Okur, Panoraia I. Siafaka, Neslihan Ü. Okur*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 31 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Schizophrenia belongs to mental illnesses affecting 1% of the worldwide population. Its therapy is still unmet; thus, researchers aimed to develop new pharmacological molecules which can improve its management.

Methods: Moreover, the current typical and atypical antipsychotics should be formulated in more efficacious systems that can deliver the drug in the brain with as few side effects as possible. Further, the development of long-acting efficient drug delivery systems could be significant in minimizing frequent dosing which is nonpreferred to schizophrenics.

Results: Herein, authors focused on current developments of antipsychotic medications used in schizophrenia management. Various studies, which include the use of first and second-generation antipsychotics, were analyzed according to their efficacy. In fact, in this review, oral, injectable, transdermal and intranasal formulations entrapped antipsychotics are presented to be valuable guidance for scientists to formulate more effective drug delivery systems for schizophrenic patients.

Conclusion: This review aimed to assist researchers working on schizophrenia management by summarizing current medications and newly synthesized drug delivery systems recently found in the literature.

Keywords: Schizophrenia, antipsychotics, oral, transdermal, intranasal, injectable.

[1]
Liu YP, Meng JH, Wu X, et al. Rs1625579 polymorphism in the MIR137 gene is associated with the risk of schizophrenia: updated meta-analysis. Neurosci Lett 2019. 713134535
[http://dx.doi.org/10.1016/j.neulet.2019.134535] [PMID: 31586698]
[2]
Annu RS, Rehman S, Md S, Baboota S, Ali J. Analyzing nanotheraputics-based approaches for the management of psychotic disorders. J Pharm Sci 2019; 108(12): 3757-68.
[http://dx.doi.org/10.1016/j.xphs.2019.08.027] [PMID: 31499066]
[3]
Palomar-Ciria N, Cegla-Schvartzman F, Lopez-Morinigo J-D, Bello HJ, Ovejero S, Baca-García E. Diagnostic stability of schizophrenia: A systematic review. Psychiatry Res 2019; 279: 306-14.
[http://dx.doi.org/10.1016/j.psychres.2019.04.020] [PMID: 31056225]
[4]
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P&T 2014; 39(9): 638-45.
[PMID: 25210417]
[5]
Siafaka PI, Barmpalexis P, Lazaridou M, et al. Controlled release formulations of risperidone antipsychotic drug in novel aliphatic polyester carriers: Data analysis and modelling. Eur J Pharm Biopharm 2015; 94: 473-84.
[http://dx.doi.org/10.1016/j.ejpb.2015.06.027] [PMID: 26159838]
[6]
Vamanu E, Gatea F. Correlations between microbiota bioactivity and bioavailability of functional compounds: A mini-review. Biomedicines 2020; 8(2): 39.
[http://dx.doi.org/10.3390/biomedicines8020039] [PMID: 32093399]
[7]
Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010; 16(5): 488-501.
[http://dx.doi.org/10.2174/138161210790361461] [PMID: 19909227]
[8]
John M. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness Comparative Effectiveness Review Summary Guides for Clinicians 2007 Internet.
[9]
Gründer G, Hippius H, Carlsson A. The ‘atypicality’ of antipsychotics: A concept re-examined and re-defined. Nat Rev Drug Discov 2009; 8(3): 197-202.
[http://dx.doi.org/10.1038/nrd2806] [PMID: 19214197]
[10]
Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14(1): 102.
[http://dx.doi.org/10.1186/1471-244X-14-102] [PMID: 24708834]
[11]
Abruzzo A, Cerchiara T, Luppi B, Bigucci F. Transdermal delivery of antipsychotics: Rationale and current status. CNS Drugs 2019; 33(9): 849-65.
[http://dx.doi.org/10.1007/s40263-019-00659-7] [PMID: 31493244]
[12]
Siafaka PI, Okur ME, Ayla Ş, Er S, Cağlar EŞ, Okur NÜ. Design and characterization of nanocarriers loaded with Levofloxacin for enhanced antimicrobial activity; physicochemical properties, in vitro release and oral acute toxicity. Braz J Pharm Sci 2019; 55: 1-13.
[http://dx.doi.org/10.1590/s2175-97902019000118295]
[13]
Siafaka PI, Üstündağ Okur N, Mone M, et al. Two different approaches for oral administration of voriconazole loaded formulations: electrospun fibers versus β-Cyclodextrin complexes. Int J Mol Sci 2016; 17(3): 282.
[http://dx.doi.org/10.3390/ijms17030282] [PMID: 26927072]
[14]
Homayun B, Lin X, Choi H-J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 2019; 11(3): 129.
[http://dx.doi.org/10.3390/pharmaceutics11030129] [PMID: 30893852]
[15]
Siafaka P, Betsiou M, Tsolou A, et al. Synthesis of folate- pegylated polyester nanoparticles encapsulating ixabepilone for targeting folate receptor overexpressing breast cancer cells. J Mater Sci Mater Med 2015; 26(12): 275.
[http://dx.doi.org/10.1007/s10856-015-5609-x] [PMID: 26543021]
[16]
Chiu L-L, Liu C-H, Chu C-L, Lin H-L, Lii S-C. Patients’ experiences of long-acting injectable antipsychotics: a qualitative study. Neuropsychiatr Dis Treat 2019; 15: 1797-804.
[http://dx.doi.org/10.2147/NDT.S206154] [PMID: 31308672]
[17]
Page VJ, Casarin A. Use of antipsychotics for the treatment of intensive care unit delirium. Rev Bras Ter Intensiva 2014; 26(2): 86-8.
[PMID: 25028943]
[18]
Siafaka PI. Preparation of new polymeric carriers, via electrospinning and phase separation methods, in order to be used as drug delivery systems Aristotle University of Thessaloniki 2016 Internet.
[19]
Ustündağ Okur N, Apaydın S, Karabay Yavaşoğlu NÜ, Yavaşoğlu A, Karasulu HY. Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. Int J Pharm 2011; 416(1): 136-44.
[PMID: 21723930]
[20]
Siafaka PI, Üstündağ Okur N, Karavas E, Bikiaris DN. Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: Current status and uses. Int J Mol Sci 2016; 17(9): 1440.
[http://dx.doi.org/10.3390/ijms17091440] [PMID: 27589733]
[21]
Tahir MA, Ali ME, Lamprecht A. Nanoparticle formulations as recrystallization inhibitors in transdermal patches. Int J Pharm 2020. 575118886
[http://dx.doi.org/10.1016/j.ijpharm.2019.118886] [PMID: 31790804]
[22]
Venkatesh MP, Liladhar PK, Kumar TMP, Shivakumar HG. In situ gels based drug delivery systems. Curr Drug Ther 2011; 6(3): 213-22.
[http://dx.doi.org/10.2174/157488511796392004]
[23]
Abbasi M, Wang S. Transdermal delivery of nanoparticles using microneedles and iontophoresis (P13-001-19). Curr Dev Nutr 2019; 3(Supplement_1)
[24]
Ita K. Transdermal iontophoretic drug delivery: Advances and challenges. J Drug Target 2016; 24(5): 386-91.
[http://dx.doi.org/10.3109/1061186X.2015.1090442] [PMID: 26406291]
[25]
Meng Q, Wang A, Hua H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int J Nanomedicine 2018; 13: 705-18.
[http://dx.doi.org/10.2147/IJN.S151474] [PMID: 29440896]
[26]
Fonseca-Santos B, Gremião MPD, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 2015; 10: 4981-5003.
[http://dx.doi.org/10.2147/IJN.S87148] [PMID: 26345528]
[27]
Lin C-H, Chen F-C, Chan H-Y, Hsu C-C. A Comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. Am J Geriatr Psychiatry 2020; 28(1): 23-30.
[http://dx.doi.org/10.1016/j.jagp.2019.08.005] [PMID: 31481273]
[28]
Lin C-H, Chen F-C, Chan H-Y, Hsu C-C. Time to rehospitalization in patients with schizophrenia receiving long-acting injectable antipsychotics or oral antipsychotics. Int J Neuropsychopharmacol 2019; 22(9): 541-7.
[http://dx.doi.org/10.1093/ijnp/pyz035] [PMID: 31260538]
[29]
Helland A, Spigset O. Serum concentrations of paliperidone after administration of the long-acting injectable formulation. Ther Drug Monit 2017; 39(6): 659-62.
[http://dx.doi.org/10.1097/FTD.0000000000000457] [PMID: 29040230]
[30]
Potkin SG, Preda A. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opin Pharmacother 2016; 17(3): 395-407.
[http://dx.doi.org/10.1517/14656566.2015.1114100] [PMID: 26864352]
[31]
Miyamoto S, Wolfgang Fleischhacker W. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry 2017; 4(2): 117-26.
[http://dx.doi.org/10.1007/s40501-017-0115-z] [PMID: 28580230]
[32]
Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E. Risperidone long-acting injection: Pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol 2010; 50(9): 1011-21.
[http://dx.doi.org/10.1177/0091270009355156] [PMID: 20097933]
[33]
Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol 2016; 9(2): 169-86.
[http://dx.doi.org/10.1586/17512433.2016.1121809] [PMID: 26573020]
[34]
Gilday EA, Nasrallah H. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials 2012; 7(1): 2-9.
[http://dx.doi.org/10.2174/157488712799363307] [PMID: 22023179]
[35]
Jann MW, Penzak SR. Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs 2018; 32(3): 241-57.
[http://dx.doi.org/10.1007/s40263-018-0508-6] [PMID: 29569082]
[36]
Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed- CORRIGENDUM. CNS Spectr 2018; 23(2): 186-6.
[http://dx.doi.org/10.1017/S1092852918000895] [PMID: 29676242]
[37]
Rothe PH, Heres S, Leucht S. Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. Schizophr Res 2018; 193: 23-8.
[http://dx.doi.org/10.1016/j.schres.2017.07.033] [PMID: 28735640]
[38]
Dening TJ, Rao S, Thomas N, Prestidge CA. Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Control Release 2016; 223: 137-56.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.047] [PMID: 26739547]
[39]
Özcan Bülbül E, Mesut B, Cevher E, Öztaş E, Özsoy Y. Product transfer from lab-scale to pilot-scale of quetiapine fumarate orodispersible films using quality by design approach. J Drug Deliv Sci Technol 2019; 54(August) 101358
[http://dx.doi.org/10.1016/j.jddst.2019.101358]
[40]
Jawahar N, Hingarh PK, Arun R, et al. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int J Biol Macromol 2018; 110: 269-75.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.01.121] [PMID: 29402457]
[41]
Joseph E, Reddi S, Rinwa V, Balwani G, Saha R. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci 2017; 104: 315-25.
[http://dx.doi.org/10.1016/j.ejps.2017.03.050] [PMID: 28408348]
[42]
Zhang X, Li Y, Huang Z, et al. Development and pharmacokinetics evaluation of quetiapine fumarate sustained-release tablets based on hydrophilic matrix. J Drug Deliv Sci Technol 2019. 54101322
[http://dx.doi.org/10.1016/j.jddst.2019.101322]
[43]
Komati S, Swain S, Rao MEB, Jena BR, Unnam S, Dasi V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Bull Fac Pharm Cairo Univ 2018; 56(2): 129-45.
[http://dx.doi.org/10.1016/j.bfopcu.2018.09.002]
[44]
Ammar HO, Ghorab MM, Mahmoud AA, Noshi SH. Formulation of risperidone in floating microparticles to alleviate its extrapyramidal side effects. Futur J Pharm Sci 2016; 2: 43-59.
[http://dx.doi.org/10.1016/j.fjps.2016.08.001]
[45]
An T, Choi J, Kim A, et al. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process. Int J Pharm 2016; 503(1-2): 8-15.
[http://dx.doi.org/10.1016/j.ijpharm.2016.02.023] [PMID: 26899975]
[46]
D’Souza S, Faraj J, DeLuca P. Microsphere delivery of Risperidone as an alternative to combination therapy. Eur J Pharm Biopharm 2013; 85(3 Pt A): 631-9.
[http://dx.doi.org/10.1016/j.ejpb.2013.07.012] [PMID: 23892159]
[47]
Ma C, Fu H, Huang Z, et al. Pharmacokinetics and pharmacodynamics evaluation on risperidone-containing microsphere fabricated by ultra-fine particle processing system. Powder Technol 2019; 358: 13-9.
[http://dx.doi.org/10.1016/j.powtec.2018.08.072]
[48]
Turek A, Borecka A, Janeczek H, Sobota M, Kasperczyk J. Formulation of delivery systems with risperidone based on biodegradable terpolymers. Int J Pharm 2018; 548(1): 159-72.
[http://dx.doi.org/10.1016/j.ijpharm.2018.06.051] [PMID: 29953927]
[49]
Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Int J Pharm 2010; 400(1-2): 49-58.
[http://dx.doi.org/10.1016/j.ijpharm.2010.08.025] [PMID: 20801200]
[50]
Silva AC, Amaral MH, González-Mira E, Santos D, Ferreira D. Solid lipid nanoparticles (SLN)-based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies. Colloids Surf B Biointerfaces 2012; 93: 241-8.
[http://dx.doi.org/10.1016/j.colsurfb.2012.01.014] [PMID: 22293602]
[51]
Ould-Ouali L, Noppe M, Langlois X, et al. Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J Control Release 2005; 102(3): 657-68.
[http://dx.doi.org/10.1016/j.jconrel.2004.10.022] [PMID: 15681087]
[52]
Bera H, Kandukuri SG, Nayak AK, Boddupalli S. Alginate-sterculia gum gel-coated oil-entrapped alginate beads for gastroretentive risperidone delivery. Carbohydr Polym 2015; 120: 74-84.
[http://dx.doi.org/10.1016/j.carbpol.2014.12.009] [PMID: 25662690]
[53]
Mudhakir D, Wibisono C, Rachmawati H. Encapsulation of risperidone into chitosan-based nanocarrier via ionic binding interaction. Procedia Chem 2014; 13: 92-100.
[http://dx.doi.org/10.1016/j.proche.2014.12.011]
[54]
Nair A, Khunt D, Misra M. Application of quality by design for optimization of spray drying process used in drying of Risperidone nanosuspension. Powder Technol 2019; 342: 156-65.
[http://dx.doi.org/10.1016/j.powtec.2018.09.096]
[55]
Kazi M, Al-Qarni H, Alanazi FK. Development of oral solid self-emulsifying lipid formulations of risperidone with improved in vitro dissolution and digestion. Eur J Pharm Biopharm 2017; 114: 239-49.
[http://dx.doi.org/10.1016/j.ejpb.2017.01.015] [PMID: 28159721]
[56]
Meola TR, Dening TJ, Prestidge CA. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro. Eur J Pharm Biopharm 2018; 129: 145-53.
[http://dx.doi.org/10.1016/j.ejpb.2018.05.028] [PMID: 29857135]
[57]
Tashan E, Karakucuk A, Celebi N. Optimization and in vitro evaluation of ziprasidone nanosuspensions produced by a top-down approach. J Drug Deliv Sci Technol 2019; 52: 37-45.
[http://dx.doi.org/10.1016/j.jddst.2019.04.024]
[58]
Koradia KD, Sheth NR, Koradia HD, Dabhi MR. Ziprasidone nanocrystals by wet media milling followed by spray drying and lyophilization: Formulation and process parameter optimization. J Drug Deliv Sci Technol 2018; 43: 73-84.
[http://dx.doi.org/10.1016/j.jddst.2017.09.011]
[59]
Zakowiecki D, Cal K, Kaminski K, et al. The improvement of the dissolution rate of ziprasidone free base from solid oral formulations. AAPS PharmSciTech 2015; 16(4): 922-33.
[http://dx.doi.org/10.1208/s12249-015-0285-1] [PMID: 25588366]
[60]
Poluri K, Mulpur E, Puttugunta SB, Govada KB. Ziprasidone hydrochloride in the treatment of schizophrenia. Int J Pharm Pharm Sci 2013; 5(2): 619-27.
[61]
Dening TJ, Rao S, Thomas N, Prestidge CA. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. Eur J Pharm Biopharm 2016; 101: 33-42.
[http://dx.doi.org/10.1016/j.ejpb.2016.01.010] [PMID: 26812284]
[62]
Bera H, Boddupalli S, Nayak AK. Mucoadhesive-floating zinc-pectinate-sterculia gum interpenetrating polymer network beads encapsulating ziprasidone HCl. Carbohydr Polym 2015; 131: 108-18.
[http://dx.doi.org/10.1016/j.carbpol.2015.05.042] [PMID: 26256166]
[63]
Bera H, Abbasi YF, Yoke FF, et al. Ziprasidone-loaded arabic gum modified montmorillonite-tailor-made pectin based gastroretentive composites. Int J Biol Macromol 2019; 129: 552-63.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.01.171] [PMID: 30707999]
[64]
Tang Y, Teng H, Shi Y, et al. Tablets of paliperidone using compression-coated technology for controlled ascending release. Asian J Pharm Sci 2018; 13(2): 143-54.
[http://dx.doi.org/10.1016/j.ajps.2017.09.005] [PMID: 32104387]
[65]
Kumar S, Randhawa JK. Preparation and characterization of Paliperidone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2013; 102: 562-8.
[http://dx.doi.org/10.1016/j.colsurfb.2012.08.052] [PMID: 23104026]
[66]
Yang C, Ji X, Pan W, et al. Paliperidone ascending controlled-release pellets with osmotic core and driven by delayed osmotic pressure. J Drug Deliv Sci Technol 2018; 48: 193-9.
[http://dx.doi.org/10.1016/j.jddst.2018.09.018]
[67]
Huang W, Shi Y, Wang C, Yu K, Sun F, Li Y. Using spray-dried lactose monohydrate in wet granulation method for a low-dose oral formulation of a paliperidone derivative. Powder Technol 2013; 246: 379-94.
[http://dx.doi.org/10.1016/j.powtec.2013.05.042]
[68]
Aleksovski A, Luštrik M, Šibanc R, Dreu R. Design and evaluation of a specific, bi-phase extended release system based on differently coated mini-tablets. Eur J Pharm Sci 2015; 75: 114-22.
[http://dx.doi.org/10.1016/j.ejps.2015.03.010] [PMID: 25845632]
[69]
Helal HM, Mortada SM, Sallam MA. Paliperidone-Loaded nanolipomer system for sustained delivery and enhanced intestinal permeation: superiority to polymeric and solid lipid nanoparticles. AAPS PharmSciTech 2017; 18(6): 1946-59.
[http://dx.doi.org/10.1208/s12249-016-0657-1] [PMID: 27914041]
[70]
Vieira SM, Michels LR, Roversi K, et al. A surface modification of clozapine-loaded nanocapsules improves their efficacy: A study of formulation development and biological assessment. Colloids Surf B Biointerfaces 2016; 145: 748-56.
[http://dx.doi.org/10.1016/j.colsurfb.2016.05.065] [PMID: 27295491]
[71]
Azum N, Rub MA, Asiri AM, Kashmery HA. Synergistic effect of an antipsychotic drug chlorpromazine hydrochloride with pluronic triblock copolymer: A physicochemical study. J Mol Liq 2018; 260: 159-65.
[http://dx.doi.org/10.1016/j.molliq.2018.03.088]
[72]
Londhe VY, Deshmane AB, Singh SR, Kulkarni YA. Lurasidone-β-cyclodextrin complexes: Physicochemical characterization and comparison of their antidepressant, antipsychotic activities against that of self microemulsifying formulation. J Mol Struct 2018; 1157: 395-400.
[http://dx.doi.org/10.1016/j.molstruc.2017.12.042]
[73]
Patel MH, Mundada VP, Sawant KK. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia. Drug Dev Ind Pharm 2019; 45(8): 1242-57.
[http://dx.doi.org/10.1080/03639045.2019.1593434] [PMID: 30880488]
[74]
Shah S, Parmar B, Soniwala M, Chavda J. Design, optimization, and evaluation of lurasidone hydrochloride nanocrystals. AAPS PharmSciTech 2016; 17(5): 1150-8.
[http://dx.doi.org/10.1208/s12249-015-0449-z] [PMID: 26586537]
[75]
Lu S, Yu P, He J-H, et al. Enhanced dissolution and oral bioavailability of lurasidone hydrochloride nanosuspensions prepared by antisolvent precipitation-ultrasonication method. RSC Advances 2016; 6(54): 49052-9.
[http://dx.doi.org/10.1039/C6RA08392G]
[76]
Al-Dhubiab BE. Aripiprazole nanocrystal impregnated buccoadhesive films for schizophrenia. J Nanosci Nanotechnol 2017; 17(4): 2345-52.
[http://dx.doi.org/10.1166/jnn.2017.12588] [PMID: 29641160]
[77]
Aggarwal G, Dhawan S. Psychotropic drugs and transdermal delivery: An overview. Int J Pharma Bio Sci 2010; 1(2)
[78]
Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Dev Ind Pharm 2013; 39(1): 39-50.
[http://dx.doi.org/10.3109/03639045.2012.657643] [PMID: 22335586]
[79]
Samanta MK, Dube R, Suresh B. Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome. Drug Dev Ind Pharm 2003; 29(4): 405-15.
[http://dx.doi.org/10.1081/DDC-120018376] [PMID: 12737534]
[80]
Sadashivaiah R, Dinesh BM. Patil U a, Raghu KS. Design and in vitro evaluation of haloperidol lactate transdermal patches containing ethyl cellulose-povidone as film formers. Asian J Pharm 2014; 2(1): 43-9.
[81]
Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002; 27(4): 684-6.
[http://dx.doi.org/10.1016/S0893-133X(02)00325-1] [PMID: 12377405]
[82]
Zhao C, Quan P, Liu C, Li Q, Fang L. Effect of isopropyl myristate on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing blonanserinretain. Acta Pharm Sin B 2016; 6(6): 623-8.
[http://dx.doi.org/10.1016/j.apsb.2016.05.012] [PMID: 27818930]
[83]
Iwata N, Ishigooka J, Kim WH, et al. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res 2019.
[PMID: 31471246]
[84]
Sambhakar S, Paliwal S, Sharma S, Singh B. Formulation of risperidone loaded proniosomes for effective transdermal delivery: An in-vitro and in-vivo study. Bull Fac Pharm Cairo Univ 2017; 55(2): 239-47.
[http://dx.doi.org/10.1016/j.bfopcu.2017.09.003]
[85]
Imam SS, Aqil M, Akhtar M, Sultana Y, Ali A. Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study. Drug Deliv 2015; 22(8): 1059-70.
[http://dx.doi.org/10.3109/10717544.2013.870260] [PMID: 24471715]
[86]
Weng W, Quan P, Liu C, Zhao H, Fang L. Design of a drug-in-adhesive transdermal patch for risperidone: Effect of drug-additive interactions on the crystallization inhibition and in vitro/in vivo correlation study. J Pharm Sci 2016; 105(10): 3153-61.
[http://dx.doi.org/10.1016/j.xphs.2016.07.003] [PMID: 27522527]
[87]
Imam SS, Ahad A, Aqil M, Akhtar M, Sultana Y, Ali A. Formulation by design based risperidone nano soft lipid vesicle as a new strategy for enhanced transdermal drug delivery: In-vitro characterization, and in-vivo appraisal. Mater Sci Eng C 2017; 75: 1198-205.
[http://dx.doi.org/10.1016/j.msec.2017.02.149] [PMID: 28415407]
[88]
Das B, Sen SO, Maji R, Nayak AK, Sen KK. Transferosomal gel for transdermal delivery of risperidone: Formulation optimization and ex vivo permeation. J Drug Deliv Sci Technol 2017; 38: 59-71.
[http://dx.doi.org/10.1016/j.jddst.2017.01.006]
[89]
Namdeo A, Garud N, Garud A. Development and evaluation of transdermal patches of quetiapine fumerate for the treatment of psychosis. Int J Drug Deliv 2012; 4(4): 470-6.
[90]
Mohawed OAM, El-Ashmoony MM, Elgazayerly ON. Niosome-encapsulated clomipramine for transdermal controlled delivery. Int J Pharm Pharm Sci 2014; 6(9): 567-75.
[91]
Shafaat K, Kumar B, Das SK, Ul Hasan R, Prajapati SK. Novel nanoemulsion as vehicles for transdermal delivery of Clozapine: In vitro and in vivo studies. Int J Pharm Pharm Sci 2013; 5(Suppl. 3): 126-34.
[92]
Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. European Neuropsychopharmacology. Elsevier BV 2019; 29: 457-70.
[93]
Suzuki H, Hibino H, Inoue Y, Takaya A. Comparisons of the effects of long-acting injectable monotherapy and combination therapy of long-acting injectable treatment with oral antipsychotics on treatment retention in patients with chronic schizophrenia. Asian J Psychiatr 2019; 39: 112-3.
[http://dx.doi.org/10.1016/j.ajp.2018.12.016] [PMID: 30605808]
[94]
Chaurasia S, Mounika K, Bakshi V, Prasad V. 3-month parenteral PLGA microsphere formulations of risperidone: Fabrication, characterization and neuropharmacological assessments. Mater Sci Eng C 2017; 75: 1496-505.
[http://dx.doi.org/10.1016/j.msec.2017.03.065] [PMID: 28415443]
[95]
Nanaki S, Tseklima M, Terzopoulou Z, et al. Use of mesoporous cellular foam (MCF) in preparation of polymeric microspheres for long acting injectable release formulations of paliperidone antipsychotic drug. Eur J Pharm Biopharm 2017; 117: 77-90.
[http://dx.doi.org/10.1016/j.ejpb.2017.03.016] [PMID: 28389342]
[96]
Shen J, Choi S, Qu W, Wang Y, Burgess DJ. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres. J Control Release 2015; 218: 2-12.
[http://dx.doi.org/10.1016/j.jconrel.2015.09.051] [PMID: 26423236]
[97]
Avachat AM, Kapure SS. Asenapine maleate in situ forming biodegradable implant: An approach to enhance bioavailability. Int J Pharm 2014; 477(1-2): 64-72.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.006] [PMID: 25305379]
[98]
Zhao J, Wang L, Fan C, et al. Development of near zero-order release PLGA-based microspheres of a novel antipsychotic. Int J Pharm 2017; 516(1-2): 32-8.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.007] [PMID: 27825865]
[99]
Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol 2017; 45(2): 364-71.
[http://dx.doi.org/10.3109/21691401.2016.1160402] [PMID: 27002542]
[100]
Katare YK, Piazza JE, Bhandari J, et al. Intranasal delivery of antipsychotic drugs. Schizophr Res 2017; 184: 2-13.
[http://dx.doi.org/10.1016/j.schres.2016.11.027] [PMID: 27913162]
[101]
Patel MR, Patel RB, Bhatt KK, Patel BG, Gaikwad RV. Paliperidone microemulsion for nose-to-brain targeted drug delivery system: pharmacodynamic and pharmacokinetic evaluation. Drug Deliv 2016; 23(1): 346-54.
[http://dx.doi.org/10.3109/10717544.2014.914602] [PMID: 24865295]
[102]
Narayan R, Singh M, Ranjan O, et al. Development of risperidone liposomes for brain targeting through intranasal route. Life Sci 2016; 163: 38-45.
[http://dx.doi.org/10.1016/j.lfs.2016.08.033] [PMID: 27593571]
[103]
Mandpe L, Pokharkar V. Targeted brain delivery of iloperidone nanostructured lipid carriers following intranasal administration: in vivo pharmacokinetics and brain distribution studies. J Nanopharm Drug Deliv 2013; 1(2): 212-25.
[http://dx.doi.org/10.1166/jnd.2013.1019]
[104]
Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008; 16(10): 806-14.
[http://dx.doi.org/10.1080/10611860802476504] [PMID: 18988064]
[105]
Ruby J, Pandey V. Formulation and evaluation of olanzapine loaded chitosan nanoparticles for nose to brain targeting an in vitro and ex vivo toxicity study. J Appl Pharm Sci 2016; 6(9): 034-40
[106]
Singh SK, Hidau MK, Gautam S, et al. Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment. Int J Biol Macromol 2018; 108: 1092-100.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.11.031] [PMID: 29126941]
[107]
Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011; 19(6): 468-74.
[http://dx.doi.org/10.3109/1061186X.2010.523787] [PMID: 20958095]
[108]
Abdelrahman FE, Elsayed I, Gad MK, Elshafeey AH, Mohamed MI. Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. Int J Pharm 2017; 530(1-2): 1-11.
[http://dx.doi.org/10.1016/j.ijpharm.2017.07.050] [PMID: 28733244]
[109]
Upadhyay P, Trivedi J, Pundarikakshudu K, Sheth N. Direct and enhanced delivery of nanoliposomes of anti schizophrenic agent to the brain through nasal route. Saudi Pharm J 2017; 25(3): 346-58.
[http://dx.doi.org/10.1016/j.jsps.2016.07.003] [PMID: 28344488]
[110]
Khunt D, Shah B, Misra M. Role of butter oil in brain targeted delivery of Quetiapine fumarate microemulsion via intranasal route. J Drug Deliv Sci Technol 2017; 40: 11-20.
[http://dx.doi.org/10.1016/j.jddst.2017.05.004]
[111]
Ayoub AM, Ibrahim MM, Abdallah MH, Mahdy MA. Sulpiride microemulsions as antipsychotic nasal drug delivery systems: In-vitro and pharmacodynamic study. J Drug Deliv Sci Technol 2016; 36: 10-22.
[http://dx.doi.org/10.1016/j.jddst.2016.09.002]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 31
Year: 2020
Published on: 16 September, 2020
Page: [3871 - 3883]
Pages: 13
DOI: 10.2174/1381612826666200523173102
Price: $65

Article Metrics

PDF: 28
HTML: 2